JP4963776B2 - Antifungal activity enhancing composition and antifungal activity enhancing method - Google Patents

Antifungal activity enhancing composition and antifungal activity enhancing method Download PDF

Info

Publication number
JP4963776B2
JP4963776B2 JP2003056459A JP2003056459A JP4963776B2 JP 4963776 B2 JP4963776 B2 JP 4963776B2 JP 2003056459 A JP2003056459 A JP 2003056459A JP 2003056459 A JP2003056459 A JP 2003056459A JP 4963776 B2 JP4963776 B2 JP 4963776B2
Authority
JP
Japan
Prior art keywords
antifungal activity
menthol
activity enhancing
antifungal
terbinafine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003056459A
Other languages
Japanese (ja)
Other versions
JP2004149508A5 (en
JP2004149508A (en
Inventor
達仁 近藤
郁夫 高木
正人 中山
保博 鳥住
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Healthcare Co Ltd
Original Assignee
Daiichi Sankyo Healthcare Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Healthcare Co Ltd filed Critical Daiichi Sankyo Healthcare Co Ltd
Priority to JP2003056459A priority Critical patent/JP4963776B2/en
Publication of JP2004149508A publication Critical patent/JP2004149508A/en
Publication of JP2004149508A5 publication Critical patent/JP2004149508A5/ja
Application granted granted Critical
Publication of JP4963776B2 publication Critical patent/JP4963776B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【0001】
【発明の属する技術分野】
本発明は、アリルアミン系抗真菌剤とメントールを含有する抗真菌活性増強型組成物、及び、メントールを含有することを特徴とする、アリルアミン系抗真菌剤の抗真菌活性増強方法に関する。
【0002】
【従来の技術】
現在の抗真菌剤の種類は、1)チオカルバメート系、2)イミダゾール系、3)アリルアミン系、4)モルフィリン系、の4系統におおよそ分類される。
【0003】
アリルアミン系の抗真菌薬としては、例えばテルビナフィン又はナフチフィンが挙げられる。
【0004】
アリルアミン系抗真菌剤について、その配合剤又は併用剤についての公知の事実としては、例えば以下のものが挙げられる。
1)アゾール耐性真菌に対し、テルビナフィンと、フルコナゾール及び/又はイトラコナゾールの組合せ剤が抗菌活性を有すること(例えば特許文献1参照)、
2)アリルアミン系抗真菌剤とトリアゾール系抗真菌剤との併用により、低濃度で顕著な抗菌活性が発現すること(例えば特許文献2参照)、
3)アリルアミン系抗真菌剤とイミダゾール系抗真菌剤との併用により、低濃度で顕著な抗菌活性が発現すること(例えば特許文献3参照)、
といった、2種の抗真菌剤の併用により有用性を高めたものがあり、また、
4)角質親和性の高い抗真菌剤に、クロタミトン等を配合すると抗真菌剤の角質浸透性・貯留性が高まること(例えば特許文献4及び特許文献5参照)が知られている。
【0005】
【特許文献1】
特表平11−504931号公報(表1乃至表3)
【特許文献2】
特開平3−38521号公報(表3及び表4)
【特許文献3】
特開平3−38522号公報(表5乃至表14)
【特許文献4】
特許第3081766号公報(表1)
【特許文献5】
米国特許第6017920号明細書(Table 1)
【0006】
【発明が解決しようとする課題】
本発明者等は、アリルアミン系抗真菌剤に併用可能な種々の医薬及び添加剤につき鋭意検討した。その結果、アリルアミン系抗真菌剤に、メントールを併用すれば、抗真菌活性が増強することを見出して、本発明を完成させた。
【0007】
【課題を解決するための手段】
本発明は、
(1)アリルアミン系抗真菌剤とメントールを含有する抗真菌活性増強型組成物、
(2)アリルアミン系抗真菌剤が、テルビナフィン又はナフチフィンである、(1)記載の抗真菌活性増強型組成物、
(3)アリルアミン系抗真菌剤が、テルビナフィンである、(1)記載の抗真菌活性増強型組成物、
(4)皮膚真菌症に用いることを特徴とする、(1)乃至(3)から選ばれるひとつに記載された抗真菌活性増強型組成物、
(5)皮膚に適用することを特徴とする、(1)乃至(3)から選ばれるひとつに記載された抗真菌活性増強型組成物、
(6)液剤、軟膏、クリーム剤、ローション剤、ゲル剤、スプレー剤であることを特徴とする、(1)乃至(3)から選ばれるひとつに記載された抗真菌活性増強型組成物、
(7)メントールを含有することを特徴とする、アリルアミン系抗真菌剤の抗真菌活性増強方法、
(8)アリルアミン系抗真菌剤が、テルビナフィン又はナフチフィンである、(7)記載の抗真菌活性増強方法、又は、
(9)アリルアミン系抗真菌剤が、テルビナフィンである、(7)記載の抗真菌活性増強方法である。
【0008】
本発明において、テルビナフィンとは、テルビナフィンまたは塩酸テルビナフィン等のテルビナフィンの塩をしめす。
【0009】
本発明において、ナフチフィンとは、ナフチフィンまたは塩酸ナフチフィン等のナフチフィンの塩をしめす。
【0010】
本発明において、メントールとは、L−メントール又はDL−メントールをしめす。
【0011】
【発明の実施の形態】
塩酸テルビナフィンは、Derivados Quimicos S.A.(スペイン)等から入手でき、塩酸ナフチフィンは、Merz Pharmaceutical(ドイツ)等から入手できる。また、L−メントールは日本薬局方に収載されており容易に入手できる。
【0012】
本発明の組成物中に含有される、アリルアミン系抗真菌剤の重量%は通常、0.1乃至10%であり、好適には、0.5乃至3%であり、メントールの重量%は通常、0.001乃至50%であり、好適には、0.01乃至20%である。
【0013】
本発明において、上記成分の他、必要に応じて他系統の抗真菌剤、角質軟化剤、殺菌剤、防腐剤、抗ヒスタミン剤、抗炎症薬、局所麻酔剤、生薬などを本発明の効果を損なわない範囲で配合することができる。
【0014】
本発明の組成物の具体的な剤形としては、例えば、液剤、軟膏、クリーム、ローション、ゲル剤、貼付剤、粉剤、スプレー剤等をあげることができ、各剤形に適した添加剤や基材を適宜使用し、日本薬局方等に記載された通常の方法に従い、製造することができる。
【0015】
【実施例】
以下に、実施例等を示し、本発明をさらに詳細に説明するが、本発明の範囲はこれらに限定されるものではない。
実施例1 軟膏剤
(1)成分
【0016】
【表1】

Figure 0004963776
(2)製法
上記成分及び分量をとり、日局製剤総則「軟膏剤」の項に準じて軟膏剤を製した後、気密容器に充てんして軟膏剤を製する。
実施例2 液剤
(1)成分
【0017】
【表2】
Figure 0004963776
(2)製法
上記成分及び分量をとり、日局製剤総則「液剤」の項に準じて液剤を製する。
実施例3 クリーム剤
(1)成分
【0018】
【表3】
Figure 0004963776
(2)製法
上記成分及び分量をとり、日局製剤総則「軟膏剤」の項に準じてクリーム剤を製した後、気密容器に充てんしてクリーム剤を製する。
実施例4 ゲル剤
(1)成分
【0019】
【表4】
Figure 0004963776
(2)製法
上記成分及び分量をとり、日局製剤総則「軟膏剤」の項に準じてゲル剤を製した後、気密容器に充てんしてゲル剤を製する。
試験例 抗真菌活性
(1)被験物質
塩酸テルビナフィンはジメチルスルホキシド、L−メントールはエタノールで溶解し、各溶媒を用い2倍希釈系列を調製した。
(2)測定方法
薬剤感受性測定方法は、日本医真菌学会標準化委員会提案微量液体希釈法(日本医真菌学会雑誌 Vol.40, 1999 p.239-257)にて行った。
【0020】
上記2倍希釈系列の各被験物質を、RPMI1640(GIBCO BRL製)にmorpholinepropanesulfonic acid(MOPS)(ナカライテスク製)を0.165(mol/L)となるように添加したMOPS-RPMI1640培地に添加し、目的濃度となるように希釈した。なお、溶媒の最終濃度は1%未満とした。
【0021】
対象菌株として白癬菌標準株(Trichophyton rubrum IFM45626及びTrichophyton rubrum IFO5807)及び臨床分離株(Trichophyton mentagrophytes臨床分離株5及びTrichophyton mentagrophytes臨床分離株6)を用い、菌量が約105/mLとなるように測定用培地に接種後、酸化還元試薬Alamar BlueTM液(和光純薬)を10%となるように添加した。なお、培養は27℃、高湿度条件下で実施した。
【0022】
Alamar Blueによる色調変化を目視により判定した。すなわち、発育コントロールが明らかに赤変した時点で判定し、陰性コントロールと同様の青色または青色を帯びた色調を示すウエルのうちの最小濃度をMIC(最大発育阻止濃度)とした。
(4)試験結果
白癬菌標準株Trichophyton rubrum IFM45626及びIFO5807に対する、塩酸テルビナフィンとL−メントールの各単剤および組合せにおけるMIC(μg/mL)値の結果を表5〜6に示す。
【0023】
【表5】
白癬菌標準株Trichophyton rubrum IFM45626の結果
Figure 0004963776
【0024】
【表6】
白癬菌標準株Trichophyton rubrum IFO5807の結果
Figure 0004963776
白癬菌Trichophyton mentagrophytes臨床分離株5及び6に対する、塩酸テルビナフィンとL−メントールの各単剤および組合せにおけるMIC(μg/mL)値の結果を表7〜8に示す。
【0025】
【表7】
白癬菌Trichophyton mentagrophytes臨床分離株5の結果
Figure 0004963776
【0026】
【表8】
白癬菌Trichophyton mentagrophytes臨床分離株6の結果
Figure 0004963776
以上、塩酸テルビナフィンとL−メントールを組み合わせることにより、抗真菌活性が増強した。
【0027】
【発明の効果】
本発明のアリルアミン系抗真菌剤とメントールを併用することにより、アリルアミン系抗真菌剤の抗真菌活性を増強することが出来る。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an antifungal activity-enhancing composition containing an allylamine antifungal agent and menthol, and a method for enhancing the antifungal activity of an allylamine antifungal agent, comprising menthol.
[0002]
[Prior art]
The types of current antifungal agents are roughly classified into four systems: 1) thiocarbamate, 2) imidazole, 3) allylamine, and 4) morphylin.
[0003]
Examples of allylamine antifungal agents include terbinafine and naphthifine.
[0004]
Regarding the allylamine antifungal agent, examples of known facts regarding the combination agent or combination agent include the following.
1) A combination of terbinafine and fluconazole and / or itraconazole has antibacterial activity against azole-resistant fungi (for example, see Patent Document 1).
2) The combined use of an allylamine antifungal agent and a triazole antifungal agent reveals a remarkable antibacterial activity at a low concentration (see, for example, Patent Document 2).
3) By combining the allylamine antifungal agent and the imidazole antifungal agent, a remarkable antibacterial activity is expressed at a low concentration (see, for example, Patent Document 3).
There are those whose usefulness has been enhanced by the combined use of two antifungal agents,
4) It is known that when crotamiton or the like is added to an antifungal agent having a high affinity for keratin, the keratin permeability / retention property of the antifungal agent is enhanced (for example, see Patent Document 4 and Patent Document 5).
[0005]
[Patent Document 1]
Japanese National Patent Publication No. 11-504931 (Table 1 to Table 3)
[Patent Document 2]
JP-A-3-38521 (Tables 3 and 4)
[Patent Document 3]
JP-A-3-38522 (Tables 5 to 14)
[Patent Document 4]
Japanese Patent No. 3081766 (Table 1)
[Patent Document 5]
US Pat. No. 6,017,920 (Table 1)
[0006]
[Problems to be solved by the invention]
The present inventors diligently studied various drugs and additives that can be used in combination with allylamine antifungal agents. As a result, it was found that antifungal activity is enhanced when menthol is used in combination with an allylamine antifungal agent, and the present invention has been completed.
[0007]
[Means for Solving the Problems]
The present invention
(1) An antifungal activity-enhancing composition containing an allylamine antifungal agent and menthol,
(2) The antifungal activity enhancing composition according to (1), wherein the allylamine antifungal agent is terbinafine or naphthifine,
(3) The antifungal activity enhancing composition according to (1), wherein the allylamine antifungal agent is terbinafine ,
(4) The antifungal activity-enhancing composition as described in one selected from (1) to (3), which is used for dermatomycosis,
(5) The antifungal activity-enhancing composition as described in one selected from (1) to (3), which is applied to the skin,
(6) The antifungal activity-enhancing composition as described in one selected from (1) to (3), which is a liquid, ointment, cream, lotion, gel, or spray.
(7) A method for enhancing the antifungal activity of an allylamine antifungal agent, comprising menthol,
(8) The antifungal activity enhancing method according to (7), wherein the allylamine antifungal agent is terbinafine or naphthifine, or
(9) The method for enhancing antifungal activity according to (7), wherein the allylamine antifungal agent is terbinafine .
[0008]
In the present invention, terbinafine refers to a terbinafine salt such as terbinafine or terbinafine hydrochloride.
[0009]
In the present invention, naphthifine refers to a salt of naphthifine such as naphthifine or naphthifine hydrochloride.
[0010]
In the present invention, menthol refers to L-menthol or DL-menthol.
[0011]
DETAILED DESCRIPTION OF THE INVENTION
Terbinafine hydrochloride can be obtained from Derivados Quimicos SA (Spain) or the like, and naphthifine hydrochloride can be obtained from Merz Pharmaceutical (Germany) or the like. Moreover, L-menthol is listed in the Japanese Pharmacopoeia and can be easily obtained.
[0012]
The weight percent of the allylamine antifungal agent contained in the composition of the present invention is usually 0.1 to 10%, preferably 0.5 to 3%, and the weight percent of menthol is usually 0.001 to 50%, preferably 0.01 to 20%.
[0013]
In the present invention, in addition to the above-mentioned components, other antifungal agents, keratin softeners, bactericides, antiseptics, antihistamines, anti-inflammatory agents, local anesthetics, herbal medicines and the like are not impaired as necessary. It can mix | blend in the range.
[0014]
Specific dosage forms of the composition of the present invention include, for example, liquids, ointments, creams, lotions, gels, patches, powders, sprays, and the like. Additives suitable for each dosage form It can be produced according to a conventional method described in Japanese Pharmacopoeia using a base material as appropriate.
[0015]
【Example】
Hereinafter, the present invention will be described in more detail with reference to examples and the like, but the scope of the present invention is not limited thereto.
Example 1 Ointment (1) Ingredient
[Table 1]
Figure 0004963776
(2) Manufacturing method After taking the above components and the amount, and making an ointment according to the section of the Japanese Pharmacopoeia General Rules “Ointment”, it is filled in an airtight container to make an ointment.
Example 2 Liquid (1) component
[Table 2]
Figure 0004963776
(2) Manufacturing method Take the above ingredients and amounts, and prepare a liquid according to the section of the “General Preparations” “Liquid”.
Example 3 Cream (1) Ingredient [0018]
[Table 3]
Figure 0004963776
(2) Manufacturing method After taking the above-mentioned components and quantities, and preparing a cream according to the section of the Japanese Pharmacopoeia General Rules “Ointment”, the cream is prepared by filling in an airtight container.
Example 4 Gel (1) component
[Table 4]
Figure 0004963776
(2) Production method After taking the above components and the amount, and producing a gel according to the section of the Japanese Pharmacopoeia General Rules “Ointment”, the gel is filled in an airtight container.
Test Example Antifungal activity (1) Test substance Terbinafine hydrochloride was dissolved in dimethyl sulfoxide, L-menthol was dissolved in ethanol, and a 2-fold dilution series was prepared using each solvent.
(2) Measuring method The drug sensitivity measuring method was performed by the micro liquid dilution method (The Journal of the Japanese Society for Medical Mycology Vol.40, 1999 p.239-257) proposed by the Japanese Society for Medical Mycology Standardization Committee.
[0020]
Each test substance in the above 2-fold dilution series is added to MOPS-RPMI1640 medium supplemented with RPMI1640 (manufactured by GIBCO BRL) and morpholinepropanesulfonic acid (MOPS) (manufactured by Nacalai Tesque) to 0.165 (mol / L). Diluted to a concentration. The final concentration of the solvent was less than 1%.
[0021]
As the target strain, standard strains of trichophyton (Trichophyton rubrum IFM45626 and Trichophyton rubrum IFO5807) and clinical isolates (Trichophyton mentagrophytes clinical isolate 5 and Trichophyton mentagrophytes clinical isolate 6) were used, so that the amount of bacteria was about 10 5 / mL. After inoculating the measurement medium, the redox reagent Alamar Blue solution (Wako Pure Chemical Industries) was added to 10%. The culture was performed at 27 ° C. and high humidity.
[0022]
The color change by Alamar Blue was judged visually. That is, it was determined when the growth control clearly turned red, and the minimum concentration of wells showing the same blue or blue color tone as the negative control was defined as MIC (maximum growth inhibitory concentration).
(4) Test results Tables 5 to 6 show the results of MIC (μg / mL) values for each single agent and combination of terbinafine hydrochloride and L-menthol for Trichophyton rubrum IFM45626 and IFO5807.
[0023]
[Table 5]
Results of Trichophyton rubrum IFM45626
Figure 0004963776
[0024]
[Table 6]
Results for Trichophyton rubrum IFO5807
Figure 0004963776
Tables 7 to 8 show the results of MIC (μg / mL) values of terbinafine hydrochloride and L-menthol alone and in combination with Trichophyton mentagrophytes clinical isolates 5 and 6.
[0025]
[Table 7]
Results of Trichophyton mentagrophytes clinical isolate 5
Figure 0004963776
[0026]
[Table 8]
Results of Trichophyton mentagrophytes clinical isolate 6
Figure 0004963776
As mentioned above, antifungal activity was enhanced by combining terbinafine hydrochloride and L-menthol.
[0027]
【Effect of the invention】
By using the allylamine antifungal agent of the present invention in combination with menthol, the antifungal activity of the allylamine antifungal agent can be enhanced.

Claims (4)

塩酸テルビナフィンとメントールを含有し、メントールが塩酸テルビナフィンの抗真菌活性を増強するために含有されていることを特徴とする組成物。 A composition comprising terbinafine hydrochloride and menthol, wherein menthol is contained to enhance the antifungal activity of terbinafine hydrochloride . 有効成分として塩酸テルビナフィンが、塩酸テルビナフィンの抗真菌活性増強剤としてメントールが含有されていることを特徴とする請求項1に記載の組成物。The composition according to claim 1, wherein terbinafine hydrochloride is contained as an active ingredient, and menthol is contained as an antifungal activity enhancer of terbinafine hydrochloride. 抗真菌活性が増強された組成物として、白癬菌Trichophyton rubrum又はTrichophyton mentagrophytesに対して用いられることを特徴とする、請求項1又は2に記載された組成物。 As a composition antifungal activity is enhanced, and wherein the Rukoto used against Trichophyton Trichophyton rubrum or Trichophyton mentagrophytes, composition according to claim 1 or 2. メントールが含有されていることを特徴とする、塩酸テルビナフィンの抗真菌活性増強剤。A terbinafine hydrochloride antifungal activity enhancer characterized by containing menthol.
JP2003056459A 2002-03-08 2003-03-04 Antifungal activity enhancing composition and antifungal activity enhancing method Expired - Fee Related JP4963776B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003056459A JP4963776B2 (en) 2002-03-08 2003-03-04 Antifungal activity enhancing composition and antifungal activity enhancing method

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002062910 2002-03-08
JP2002062910 2002-03-08
JP2002259798 2002-09-05
JP2002259798 2002-09-05
JP2003056459A JP4963776B2 (en) 2002-03-08 2003-03-04 Antifungal activity enhancing composition and antifungal activity enhancing method

Publications (3)

Publication Number Publication Date
JP2004149508A JP2004149508A (en) 2004-05-27
JP2004149508A5 JP2004149508A5 (en) 2006-04-13
JP4963776B2 true JP4963776B2 (en) 2012-06-27

Family

ID=32475129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003056459A Expired - Fee Related JP4963776B2 (en) 2002-03-08 2003-03-04 Antifungal activity enhancing composition and antifungal activity enhancing method

Country Status (1)

Country Link
JP (1) JP4963776B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099932A1 (en) 2003-06-25 2007-05-03 Toshihiro Shirouzu External preparation for athlete's foot treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3081766B2 (en) * 1994-05-06 2000-08-28 東興薬品工業株式会社 Keratin storage type antifungal external composition
AU3618795A (en) * 1994-10-05 1996-05-02 Hisamitsu Pharmaceutical Co., Inc. Drug compounding ingredients comprising n-substituted-o-toluidine derivative and percutaneously absorbable preparation
JP3461401B2 (en) * 1995-02-01 2003-10-27 久光製薬株式会社 Transdermal tape
JP4253047B2 (en) * 1996-09-27 2009-04-08 杏林製薬株式会社 Film-forming antifungal composition
JPH10306034A (en) * 1997-05-08 1998-11-17 Nippon Mokutan Kk Cutaneous remedy
GB9810799D0 (en) * 1998-05-21 1998-07-15 Boots Co Plc Antimicrobial agent
JP2001131018A (en) * 1999-10-29 2001-05-15 Hirase Shizuka Functional composition

Also Published As

Publication number Publication date
JP2004149508A (en) 2004-05-27

Similar Documents

Publication Publication Date Title
DE60204322T2 (en) NITROGEN MONOXIDE FORMING COMPOSITIONS FOR THE TREATMENT OF NAIL BED INFECTIONS
WO2000062776A1 (en) Antifungal compositions
WO1996040121A1 (en) Antifungal agent
KR20190037229A (en) A synergistic antifungal composition and method thereof
AU2002318001A1 (en) Treatment of nail infections with NO
CN116585257A (en) Compositions, systems, kits and methods for treating infections
JP2006306734A (en) External preparation blended with urea
JP5832302B2 (en) Compositions, uses and methods of use of surface active proteins in topical drug delivery to keratin
JP4963776B2 (en) Antifungal activity enhancing composition and antifungal activity enhancing method
JP3941132B2 (en) Antifungal
EP3861983A1 (en) Novel sertaconazole compositions
JP2004035411A5 (en)
JP5559449B2 (en) Antifungal composition
JP4692280B2 (en) Antifungal composition
JP3793596B2 (en) Antifungal composition for external use
WO2014017411A1 (en) External preparation for treating trichophytosis unguium
JP4730094B2 (en) Antifungal
JP5539300B2 (en) Antifungal composition
JP2019006752A (en) Composition for oral cavity
CN107865825B (en) Luliconazole external spray pharmaceutical composition and preparation method thereof
JP4875813B2 (en) Antifungal composition
KR20160121538A (en) Topical antifungal composition for treating onychomycosis
CN115444852A (en) Application of mitochondria-targeted amide compound in preparation of antifungal drugs
Rao et al. FORMULATION DEVELOPMENT OF MEDICATED VANISHING CREAM FOR THE TREATMENT OF TINEA CAPITIS SCALP DISEASE IN CHILDREN
JP2019006751A (en) Composition for oral cavity

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20040811

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20050517

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050602

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060222

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20060524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090821

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090916

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091104

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20091216

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120327

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150406

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees